BioCentury
ARTICLE | Clinical News

Irofulven hydroxymethylacylfulvene: Phase I

June 9, 2003 7:00 AM UTC

In preliminary results from an ongoing open-label Phase I study in 24 patients with solid tumors, irofulven plus gemcitabine did not impact the pharmacokinetic profile of either drug. The most common ...